Enzyme is pleased to announce that it is joining Rayls as a launch partner, bringing Enzyme Onyx and Enzyme Myso natively to the Rayls network. This marks a significant step in Enzyme's commitment to making institutional-grade tokenized fund infrastructure available wherever regulated financial markets are building on-chain.
Enzyme Onyx and Enzyme Myso: A Brief Overview
Enzyme Onyx is the complete technical stack for issuing, structuring, and administering tokenized funds and financial instruments. Built for the innovators of modern markets, Onyx gives enterprises the freedom to create and manage fully tokenized strategies across any asset class, network, and financial system. From tokenized hedge funds, money market funds, and mutual funds to structured financial instruments, Onyx provides institutional-grade infrastructure covering the full lifecycle of a tokenized vehicle (including accounting, subscriptions, redemptions, NAV reporting, fee management, and investor onboarding) all delivered in a white-label environment that enterprises can deploy as their own.
Enzyme Myso is the premier protocol for creating, trading, and managing fully customizable on-chain options strategies. Myso enables issuers and trading firms to create and sell bespoke covered calls and cash-secured puts, settling on-chain either through its automated marketplace or over-the-counter. With deep cross-firm liquidity, non-custodial settlement, and a wide range of configurable parameters, from strike prices and expiries to auction mechanics and premium structures, Myso brings institutional-grade derivatives infrastructure entirely on-chain, eliminating counterparty risk and intermediary friction.
Until now, both protocols have operated exclusively within the Ethereum ecosystem. Going forward, they will be available as Rayls-native platforms as well, extending their reach to one of the most consequential institutional blockchain networks in the world.
Expanding the Institutional Frontier: Why Rayls, and Why Now
Rayls is an EVM-compatible Layer 1 blockchain built specifically for financial institutions. Its architecture combines a compliant public chain with a network of private institutional nodes, enabling banks and regulated institutions to issue, settle, and manage financial assets on-chain while retaining the data privacy and compliance controls their operations require.
What distinguishes Rayls from most institutional blockchain networks is the depth of its real-world deployment. Rayls has been selected by the Central Bank of Brazil for the Drex wholesale CBDC pilot and is already installed within 16 of the largest banks in the region. Núclea, a leading financial market infrastructure provider, is utilizing Rayls to tokenize commercial receivables at scale, bringing high-volume financial assets onto a transparent, on-chain ledger. The network's global technical credibility is further evidenced by its performance in J.P. Morgan's Project EPIC benchmark. This evaluation of privacy-focused blockchain solutions for institutional finance ranked Rayls among the leading candidates.
By joining Rayls as a launch partner, Enzyme is ensuring that its global infrastructure for tokenized finance is integrated with an infrastructure built to handle the complexity and scale of modern, regulated capital markets.
What Enzyme Onyx and Myso Bring to Rayls
By deploying Enzyme Onyx and Enzyme Myso natively to Rayls, we are enabling two pivotal financial use cases to operate within this institutional-grade ecosystem for the first time.
Tokenized Funds supporting on-chain and off-chain asset classes, Natively on Rayls
With Enzyme Onyx on Rayls, fund managers will be able to deploy and operate fully tokenized investment funds directly within the Rayls blockchain with the flexibility to run strategies spanning on-chain assets such as cryptocurrencies, and off-chain asset classes including equities, fixed income, T-Bills, real estate, and beyond. This means fund vehicles, including their subscription logic, valuation mechanisms, allocation policies, and redemption flows, will benefit from Rayls' privacy-preserving and compliant architecture, where sensitive portfolio data is visible only to the appropriate counterparties, while settlement and synchronization occur in real time across participants.
For fund administrators, institutional investors, and asset managers engaging with the Rayls ecosystem, this represents a meaningful step toward a fully native on-chain infrastructure that meets the standards of professional capital markets.
Options Strategies : Calls and Puts Natively on Rayls
Enzyme Myso on Rayls will bring structured derivatives to the network in a fully native and on-chain form. Institutions and sophisticated counterparties will be able to construct, issue, and settle Covered Calls and Cash-Secured Put options entirely within the Rayls environment, utilizing the privacy-preserving settlement and compliance controls that the network provides.
This opens the door to on-chain derivatives infrastructure that does not compromise on confidentiality, counterparty controls, or regulatory compliance, making Myso a natural fit for the institutional actors and financial intermediaries who are building on Rayls.
Our Commitment to Multi-Chain Infrastructure
Expanding to Rayls reflects a principle for us: institutional tokenized finance will not settle on a single network. Different markets, different regulatory environments, and different institutional ecosystems will build on different infrastructure, and Enzyme's role is to be the operational layer that works across all of them.
